Overview

Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung Cancer

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether giving chemotherapy together with radiation therapy is more effective with or without adjuvant chemotherapy in treating unresectable stage II or stage III non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying giving paclitaxel, carboplatin, and radiation therapy together with adjuvant paclitaxel and carboplatin to see how well it works compared to giving paclitaxel, carboplatin, and radiation therapy alone in treating patients with unresectable stage II or stage III non-small cell lung cancer.

Phase:

Phase 3

Details

Lead Sponsor:

GERCOR - Multidisciplinary Oncology Cooperative Group
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel